Liquid biopsy

EDGC pursues the growth of both individuals and organizations,
challenging constantly and cooperating each other.

Liquid biopsy

Liquid Biopsy for Early Diagnosis of Cancer, Monitoring Cancer, Companion Diagnostics, and Organ Transplant Rejection Monitoring without the Need for Tissue Biopsy

Liquid Biopsy, a non-invasive alternative to tissue biopsy, can help determine cancer treatments by identifying clinically relevant biomarkers.


  • No need to extract tissue samples

  • Minimizing Interpretation

  • Minimizing deviation

  • Detailed description for cancer treatment

Liquid biopsy can be used for early diagnosis (screening), recurrence of cancer (monitoring), and anticancer drug effect (companion diagnostics) using Circulating Tumor Cell* (CTC), a cfDNA derived from cancer cells. The cancer cell-derived cfDNA is analyzed through NGS technology and bioinformatics to see if there is a mutation that causes cancer, and whether it can be effective against the anticancer drug. It is a state-of-the-art personalized precision medical service that confirms whether there are cancer cells.*Circulating Tumor Cell (CTC): Cancer cells circulating in blood vessels

Test Options

Test Details

No posts found.